Blog - Advanced Medicine In China

12 months ago

2024 EHA | New Generation BCL-2 Inhibitor Sonrotoclax Expected to Be a New Treatment Option for RRMM

**2024 EHA | New Generation BCL-2 Inhibitor Sonrotoclax Expected to Be a New Treatment Option for RRMM** RRMM The 29th Annual Meeting of the European Hematology Association (EHA) was held from Ju...

12 months ago

Indications for Kymriah Approval in Europe

Indications for Kymriah Approval in Europe In early May 2022, Novartis announced that the European Commission (EC) has approved the CAR-T cell therapy Kymriah (tisagenlecleucel) for the treatment o...

12 months ago

Real-World Experience Comparing Kymriah and Yescarta for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) in 307 Cases

Real-World Experience Comparing Kymriah and Yescarta for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) in 307 Cases Several CAR-T products have been approved for the treatme...

12 months ago

Kite Pharma Yescarta (Axicabtagene Ciloleucel) Product Information

Kite Pharma Yescarta (Axicabtagene Ciloleucel) Product Information Generic Name: Axicabtagene Ciloleucel Injection Brand Name: Yescarta Indications 1. Large B-Cell Lymphoma Yescarta is indicated fo...

12 months ago

Sustained 7-Month CR, Liver Extramedullary Disease Disappearance: Equecabtagene Autoleucel Brings High-Quality Survival Hope to Ultra-High-Risk RRMM Patients with Extramedullary Disease

### Sustained 7-Month CR, Liver Extramedullary Disease Disappearance: Equecabtagene Autoleucel Brings High-Quality Survival Hope to Ultra-High-Risk RRMM Patients with Extramedullary Disease RRMM Pa...

12 months ago

What are the adverse reactions after CAR-T cell reinfusion?

Interpretation of Hot Topics Conerning Mutiple Myeloma Patients: “What are the adverse reactions after CAR-T cell reinfusion?” Process Diagram for Myeloma Patients Receiving CAR-T ...

12 months ago

Maximum Intention-to-Treat Analysis of Kite Pharma’s Tecartus (Brexucabtagene autoleucel) for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Maximum Intention-to-Treat Analysis of Kite Pharma’s Tecartus (Brexucabtagene autoleucel) for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Patients with relapsed/refrac...

12 months ago

What are Kite FDA Approved CAR-T Cell Therapies

What are Kite FDA Approved CAR-T Cell Therapies Introduction to Kite Company Kite, a pioneering biotechnology company, has firmly established itself as a leader in the development of novel cancer i...

12 months ago

Kite CAR-T Approval Overview

Kite CAR-T Approval Overview Introduction to Kite Pharma Kite Pharma, a subsidiary of Gilead Sciences, is a leading biopharmaceutical company focused on developing innovative cancer immunotherapies...

12 months ago

2024 EBMT : China’s First RRMM CAR-T Therapy Equecabtagene Autoleucel: Efficacy Unaffected by Patients’ Baseline sBCMA Plasma Levels

2024 EBMT : China’s First RRMM CAR-T Therapy Equecabtagene Autoleucel: Efficacy Unaffected by Patients’ Baseline sBCMA Plasma Levels RRMM In recent years, CAR-T cell therapy targeting B...

12 months ago

2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients

**2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients** Multiple Myeloma Multiple Myeloma (MM) is a malig...

12 months ago

#EBMT / #EHA Leading the Frontiers of Medicine: China’s Top Medical Expert Explains the Groundbreaking CAR-T Cell Therapy

#EBMT / #EHA Leading the Frontiers of Medicine: China’s Top Medical Expert Explains the Groundbreaking CAR-T Cell Therapy Expert:**Huang He** Chief Physician and Doctoral Supervisor. C...

Menu

Our Blog